Homocysteine Is Associated With Future Venous Thromboembolism in 2 Prospective Cohorts of Women

Abstract

[Figure: see text].

Trial registration: ClinicalTrials.gov NCT00000541 NCT00000479.

Keywords: biomarker; homocysteine; plasma; pulmonary embolism; venous thromboembolism.

Figures

Figure 1.. Risk of Incident VTE, PE, and DVT by Baseline BMI and Homocysteine Concentration

Participants are divided into low/high categories based on the study population median for body mass index (24.9 kg/m2) and plasma homocysteine (10.5 μmol/L). VTE indicates venous thromboembolism; PE, pulmonary embolism; DVT, deep vein thrombosis; BMI, body mass index; Hcys, homocysteine; CI, confidence interval. Adjusted for age, smoking, hormonal therapy, activity level, metabolic syndrome, post-menopausal status, glomerular filtration rate, and randomized treatment.

Figure 2.. Association Between Homocysteine and Incident VTE in WHS and WAFACS

Hazard ratios and 95% confidence intervals for homocysteine in both WHS and WAFACS. WHS indicates Women’s Health Study; WAFACS, Women’s Antioxidant and Folic Acid Cardiovascular Study. Models for WHS adjusted for age, smoking, BMI, hormonal therapy, activity level, metabolic syndrome, post-menopausal status, glomerular filtration rate, and randomized treatment. Models for WAFACS adjusted for age, smoking, BMI, height, activity level, diabetes, post-menopausal status, history of hypertension, randomized treatment, and baseline venous thromboembolism.